Gen İlaç (GENIL) Fundamental Analysis
This page summarises the financial statements and the KapAI scorecard of Gen İlaç (GENIL) in the İlaç ve Sağlık sector for the 2026/6 period. Figures are compiled from the company’s reported balance sheet and income statement, in millions of Turkish lira.
Company Information
- Company: Gen İlaç
- Ticker: GENIL
- Sector: İlaç ve Sağlık
- Latest reporting period: 2026/6
KapAI Scorecard
Overall score: 3.2 / 5
- Profitability: 4.5 / 5
- Liquidity: 2.1 / 5
- Leverage: 2.6 / 5
- Efficiency: 3.7 / 5
Summary Income Statement (TRY million)
Period: 2026/6 · Compared with: 2025/6
| Item | 2026/6 | 2025/6 | Change |
|---|---|---|---|
| Revenue | 14,055 | 11,069 | +27.0% |
| Gross Profit | 3,574 | 2,340 | +52.7% |
| Operating Profit | 2,050 | 1,223 | +67.6% |
| EBITDA | 0 | 0 | — |
| Net Monetary Position Gains | -210 | 47 | -548.5% |
| Net Profit for the Period | 889 | 546 | +63.0% |
Summary Balance Sheet (TRY million)
Period: 2026/6 · Compared with: 2025/6
| Item | 2026/6 | 2025/6 | Change |
|---|---|---|---|
| Current Assets | 12,006 | 8,294 | +44.8% |
| Non-Current Assets | 11,570 | 7,964 | +45.3% |
| Total Assets | 23,576 | 16,257 | +45.0% |
| Current Liabilities | 9,314 | 6,390 | +45.8% |
| Non-Current Liabilities | 1,210 | 944 | +28.2% |
| Total Liabilities | 10,524 | 7,334 | +43.5% |